Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A global Phase 3 Randomized Clinical Trial Evaluating Adjuvant Darovasertib in Patients With Primary Uveal Melanoma (UM), Including Both HLA-A2–Negative and –Positive Patients

Next Previous
Trial Profile

A global Phase 3 Randomized Clinical Trial Evaluating Adjuvant Darovasertib in Patients With Primary Uveal Melanoma (UM), Including Both HLA-A2–Negative and –Positive Patients

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darovasertib (Primary)
  • Indications Uveal melanoma
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 05 Nov 2025 New trial record
  • 02 Sep 2025 According to a Servier media release, IDEAYA and Servier plan to launch a global phase 3 randomized clinical trial in 2026 to evaluate adjuvant darovasertib in patients with primary uveal melanoma (UM), including both HLA-A2-negative and -positive patients.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top